JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A4135 Tofacitinib (CP-690550) Citrate
2 Citation

Target: JAK

Summary: Potent JAK inhibitor

≥25.22 mg/mL
A4138 Tofacitinib (CP-690550,Tasocitinib)
1 Citation

Target: JAK

Summary: Janus kinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥15.6 mg/mL
A4317 Apremilast (CC-10004)

Target: Phosphodiesterases (PDEs)

Summary: PDE4 inhibitor

≥23.05 mg/mL
A4347 Methotrexate
2 Citation

Target: Folate Analogue

Summary: Folate antagonist,inhibits DFHR

≥21.55 mg/mL
A1926 CA 074
2 Citation

Target: Cathepsins

Summary: Cathepsin B inhibitor

≥19.17 mg/mL
A3284 Cathepsin S inhibitor
1 Citation

Target: Cathepsins

Summary: Blocks MHCII antigen presentation

≥24.25 mg/mL
B4664 T-5224
10 Citation

Target: AP-1|MMP

Summary: C-Fos/AP-1 inhibitor

≥25.88 mg/mL
B1112 Merimepodib

Target: IMPDH

Summary: Novel noncompetitive inhibitor of IMPDH(Inosine monophosphate dehydrogenase).

≥45.2 mg/mL
A8238 VX-765
1 Citation

Target: Caspases

Summary: Caspase-1 inhibitor,potent and selective

insoluble in H2O; ≥313 mg/mL